Angios Biotech is an Austrian biotechnology company focused on innovative cell-based therapies aimed at treating vascular diseases. The company has developed a patented technology that utilizes induced pluripotent stem cells (iPSC) to create blood vessels of human origin. This unique model accurately mimics human vascular pathologies, providing a relevant platform for research and development in vascular diseases. Angios is particularly advancing antibody targets for diabetic vasculopathies in collaboration with Abcellera Biologics and is also working on regenerative treatments for vascular transplants.

In addition to its therapeutic approaches, Angios has created a proprietary Blood Vessel Organoid model, which serves as an animal-free drug testing platform. This model addresses the limitations of traditional animal testing, which often fails to accurately represent human vascular responses and can lead to high rates of clinical trial failures due to unpredicted cardiovascular toxicity. By developing a toxicity scoring system based on this organoid model, Angios aims to enhance the predictive capabilities for assessing the vascular toxicity of new drug candidates, thereby improving the drug development process and reducing reliance on animal models.

Austria

Angios is a biotechnology company, specializing in vascular research to improve patients' lives all over the world. We are based in the beautiful city of Innsbruck. We strive to develop new treatments for challenging diabetic vascular diseases by pursuing pre-identified targets for diabetic retinopathy and by leveraging the vascular organoid model developed in the laboratories of our founders.

Angios Biotech

Company Details